Even though the scientific relevance of the aforementioned cardiovascular threat factor alterations by tirzepatide is going to be assessed inside the planned cardiovascular end result research SURPASS-CVOT ( "type":"clinical-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Exa